Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists
复制标题
DOI：
10.1016/j.jaad.2020.06.051
复制
发表时间：
2020-10-01
影响因子：
13.8
通讯作者：
Merola, Joseph F.
中科院分区：
文献类型：
--
作者：
Niaki, Omid Zahedi;Anadkat, Milan J.;Merola, Joseph F.
在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行的背景下，治疗免疫介导的皮肤病的皮肤科医生现在必须应对与免疫抑制剂使用相关的不确定性。尽管许多常用免疫抑制剂的感染风险仍然很低，但评估此类药物在2019冠状病毒病（COVID-19）中安全性的直接数据很少。本文基于目前可用的安全性数据和免疫介导的皮肤病患者的最新COVID-19结局数据进行综述并提供指导。跨学科专家小组强调在免疫抑制治疗的管理中采取逐步的、共同的决策方法。本文的目的是帮助提供者最大限度地减少疾病突发的风险，同时最大限度地减少在不断发展的大流行期间医源性伤害的风险。
Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in coronavirus disease 2019 (COVID-19) are scarce. This article reviews and offers guidance based on currently available safety data and the most recent COVID-19 outcome data in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasizes a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic.